danusertib
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2007 (NCT00335868)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
Serine/threonine-protein kinase Aurora inhibitor
Pan-Aurora kinase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1- Mol. weight
- 474.57 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL402548 ↗
Also known as
- danusertib
- danusertib
- danusertib
- danusertib
- danusertib
- pha739358
- pha 739358
- pha-739358
- pha-739358
- pha-739358
- pha-739358
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00872300 | Phase 2 | Oct 1, 2008 | Nerviano Medical Sciences |
| NCT00766324 | Phase 2 | Sep 1, 2007 | Nerviano Medical Sciences |
| NCT00335868 | Phase 2 | Mar 1, 2007 | National Cancer Institute (NCI), University of California, Los Angeles |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nerviano Medical Sciences | For profit | 2 | 2 | 1 | 2007 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2007 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2007 |
3 organizations
Page 1 / 1